185 related articles for article (PubMed ID: 3124285)
1. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
3. [Quantification of a specific inhibitor (PAI-1) of tissue-type plasminogen activator (t-PA) in the plasma].
Masson C; Angles-Cano E
Ann Biol Clin (Paris); 1989; 47(5):269-74. PubMed ID: 2500878
[TBL] [Abstract][Full Text] [Related]
4. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
5. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
6. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
7. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
Carr ME; Krishnamurti C; Alving BM
Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
9. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of plasminogen activator in human plasma using the method of fibrin/celite column chromatography--with special reference to the determination of fibrin adsorbable tissue-plasminogen activator by ELISA].
Ieko M
Hokkaido Igaku Zasshi; 1985 Nov; 60(6):834-47. PubMed ID: 4085966
[TBL] [Abstract][Full Text] [Related]
11. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress.
Jern C; Selin L; Jern S
Thromb Haemost; 1994 Aug; 72(2):285-91. PubMed ID: 7831666
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
[TBL] [Abstract][Full Text] [Related]
13. A sensitive solid-phase immunosorbent assay for tissue-type plasminogen activator activity in plasma using trinitrobenzoylated poly-D-lysine as a stimulator for plasminogen activation.
Petersen LC; Handest P; Brender J; Selmer J; Jørgensen M; Thorsen S
Thromb Haemost; 1987 Apr; 57(2):205-11. PubMed ID: 3110997
[TBL] [Abstract][Full Text] [Related]
14. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
15. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
[TBL] [Abstract][Full Text] [Related]
16. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Francis RB; McGehee WG; Feinstein DI
Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
[TBL] [Abstract][Full Text] [Related]
17. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.
Grimaudo V; Bachmann F; Hauert J; Christe MA; Kruithof EK
Thromb Haemost; 1992 Apr; 67(4):397-401. PubMed ID: 1631786
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
